STRO

Over the past six months, Sutro Biopharma reported Q1 2026 revenue of $14.5 million and a net loss of $44.1 million, with cash totaling $202.6 million, extending its cash runway into at least Q2 2028. Q2 2026 results showed revenue of $9.8 million and a net loss of $38.5 million, with cash at $164.3 million, also expected to fund operations into at least Q2 2028. Clinical updates included preclinical AACR 2026 results showing robust antitumor activity for next-generation ADCs, initial Phase 1 data for STRO-004 showing partial responses and favorable tolerability, STRO-006 remaining on track for Phase 1 in Q3 2026, STRO-227 expected to file an IND in 2026, and an Astellas-partnered TROP2 iADC entering the clinic, triggering a $10 million milestone. The company completed an underwritten offering of 7,868,383 common shares at $13.98 per share, raising approximately $110.0 million, which contributed to extending its cash runway. The stock price decreased by 36.08% over the last six months and 26.79% over the last month, but increased by 76.74% over the last year as of September 24, 2026.